麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02335 麦科医药-B

未开盘 09-09 16:08:04

26.040

-0.060

-0.23%

最高26.520	最低25.000	成交量61.78万
今开26.080	昨收26.100	日振幅5.82%
总市值86.39亿	流通市值72.93亿	总股本3.32亿
成交额1,610万	换手率0.22%	流通股本2.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02335","market":"HK","secType":"STK","nameCN":"麦科医药-B","latestPrice":26.04,"timestamp":1788941284676,"preClose":26.1,"halted":0,"volume":617800,"delay":0,"changeRate":-0.002298850574712731,"floatShares":280071100,"shares":331740350,"eps":0,"marketStatus":"未开盘","change":-0.06,"latestTime":"09-09 16:08:04","open":26.08,"high":26.52,"low":25,"amount":16103444,"amplitude":0.058238,"askPrice":26.24,"askSize":600,"bidPrice":26.04,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.265,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789003800000},"marketStatusCode":0,"adr":0,"listingDate":1782230400000,"exchange":"SEHK","adjPreClose":26.1,"openAndCloseTimeList":[[1788917400000,1788926400000],[1788930000000,1788940800000]],"volumeRatio":1.0311171049682493,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02335","defaultTab":"news","newsList":[{"id":"1146317035","title":"麦科医药-B H股获纳入沪深港通合资格股份名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1146317035","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146317035?lang=zh_cn&edition=full","pubTime":"2026-09-07 21:55","pubTimestamp":1788789331,"startTime":"0","endTime":"0","summary":"2026年9月7日，麦科医药-B（02335）发布自愿性公告称，公司H股已被上海证券交易所和深圳证券交易所分别于2026年9月4日及2026年9月7日公告纳入股票互联互通机制（沪港通及深港通）合资格股份名单，相关安排自2026年9月7日起生效。\n股份纳入互联互通后，中国内地的合资格投资者可通过上海证券交易所及深圳证券交易所买卖麦科医药-B的H股。\n公司在公告中指出，进入合资格名单有助于进一步扩大股东基础并提升股份的交易流动性。\n麦科医药-B董事会主席、首席执行官兼执行董事为王冰博士，公告于2026年9月7日在西安发布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665312548","title":"麦科医药-B(02335.HK)获纳入股票互联互通机制(沪港通及深港通)股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665312548","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665312548?lang=zh_cn&edition=full","pubTime":"2026-09-07 21:52","pubTimestamp":1788789133,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149812159","title":"麦科医药-B发布2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149812159","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149812159?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:58","pubTimestamp":1788339483,"startTime":"0","endTime":"0","summary":"2026年9月2日，陕西麦科奥特医药科技股份有限公司发布截至2026年8月31日的股份变动月报表。报告显示，公司已发行股份总数及注册股本在报告期内保持不变。公司披露，截至2026年8月31日，H股已发行股份为280,071,100股，内资股已发行股份为51,669,250股，两类股份数量与上月底相比均未出现增加或减少。公司表示，截至报告期末，股本数及股本结构保持稳定。本次公告由执行董事王冰签署。公司后续将继续按规定及时披露公司股份变动等相关信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662993500","title":"麦科医药上市首份中报亮相：经营现金流转正","url":"https://stock-news.laohu8.com/highlight/detail?id=2662993500","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662993500?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:01","pubTimestamp":1787925660,"startTime":"0","endTime":"0","summary":"    本报讯(记者殷高峰)8月28日，陕西麦科奥特医药科技股份有限公司(以下简称“麦科医药”)发布港交所上市后首份中期业绩。报告期内，核心管线迎来密集里程碑，经营现 ...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://baijiahao.baidu.com/s?id=1874775252433885287&wfr=spider&for=pc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1781763978866","symbols":["02335","159399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662056325","title":"麦科医药－Ｂ(02335.HK)中期亏损约2.32亿元 同比增加364.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662056325","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662056325?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:47","pubTimestamp":1787892424,"startTime":"0","endTime":"0","summary":"格隆汇8月28日丨麦科医药－Ｂ(02335.HK)发布截至2026年6月30日止六个月中期业绩。于报告期内，集团录得期内亏损约人民币2.32亿元，同比增加364.3%。集团的经调整亏损净额约为人民币1.12亿元，较2025年同期增加128.5%。该增加乃主要归因于研发活动的投资增加。集团录得经营活动所得现金净额约人民币1.09亿元，而2025年同期则为经营活动所用现金净额约人民币5230万元，实现了从经营现金流出净额到经营现金流入净额的转变。此乃主要归因于收到来自云顶新耀的预付款人民币2亿元。基本每股亏损0.88元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260828/32351515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662305521","title":"麦科医药-B(02335.HK)发布中期业绩 股东应占亏损2.31亿元 同比扩大372.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662305521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662305521?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:30","pubTimestamp":1787891448,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179480337","title":"陕西麦科医药科技股份有限公司——2026年上半年亏损2.317亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1179480337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179480337?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:18","pubTimestamp":1787890689,"startTime":"0","endTime":"0","summary":"陕西麦科医药科技股份有限公司（麦科医药-B）公布了截至2026年6月30日的六个月财务报告。数据显示，该公司在此期间录得亏损人民币2.317亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182025114","title":"麦科医药-B披露MT200605治疗急性缺血性脑卒中II期试验完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1182025114","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182025114?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:46","pubTimestamp":1787755606,"startTime":"0","endTime":"0","summary":"2026年8月26日，陝西麥科奧特醫藥科技股份有限公司公告，其自主研发的候选药物MT200605用于急性缺血性脑卒中的II期随机、双盲、安慰剂对照试验已在中国完成。该试验共入组360名受试者，并按1:1:1:1比例随机分配至10 mg BID组、20 mg BID组、40 mg BID组及安慰剂组，连续静脉输注14天。安全性数据显示，MT200605以剂量依赖方式降低AIS患者急性肾损伤发生率，高剂量组AKI发生率较安慰剂组降低80%以上。本次公告为公司自愿披露，旨在更新业务进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662742710","title":"麦科医药-B(02335)：MT200605用于急性缺血性脑卒中(AIS)的II期临床试验在中国完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2662742710","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662742710?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:40","pubTimestamp":1787755220,"startTime":"0","endTime":"0","summary":"智通财经APP讯，麦科医药-B(02335)公布，集团自主研发的用于治疗急性缺血性脑卒中的候选药物MT200605的II期临床试验已完成。该临床试验已证明具有显著且稳健的疗效优势及良好的安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","02335","IBBJ","AIS","MDTX","IBBQ","BK1161","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662320734","title":"麦科医药-B(02335)存仓市值总计5.21亿港元 股东将1773.41万股股票存入Merrill Lynch Far East","url":"https://stock-news.laohu8.com/highlight/detail?id=2662320734","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662320734?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:07","pubTimestamp":1787620021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月24日，麦科医药-B(02335)出现存仓异动，存仓市值总计5.21亿港元，占比6.33%。该公司股东将1773.41万股股票存入Merrill Lynch Far East。\r\n\r\n　　麦科医药发布公告，根据恒生指数有限公司于2026年8月21日公布的截至2026年6月30日止期间的恒生指数系列季度检讨结果，公司已获选并将纳入为恒生综合指数(恒生综指)成份股，自2026年9月7日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260825/32345698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661240441","title":"麦科医药-B(02335)获纳入恒生综合指数成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661240441","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661240441?lang=zh_cn&edition=full","pubTime":"2026-08-24 12:11","pubTimestamp":1787544686,"startTime":"0","endTime":"0","summary":"智通财经APP讯，麦科医药-B(02335)发布公告，根据恒生指数有限公司于2026年8月21日公布的截至2026年6月30日止期间的恒生指数系列季度检讨结果，本公司已获选并将纳入为恒生综合指数(恒生综指)成份股，自2026年9月7日起生效。于获纳入恒生综指成份股后，本公司H股预期将符合资格获纳入沪港通及深港通。沪港通及深港通是香港与中国内地资本市场投资者进行股票交易及投资的渠道。董事会相信，获纳入恒生综指反映资本市场对本公司价值及成长潜力的认可，这将有助于拓宽本公司股东基础及提升其H股的交易流动性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02335","BK1161","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105527001","title":"麦科医药-B（02335）将于9月7日纳入恒生综合指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1105527001","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105527001?lang=zh_cn&edition=full","pubTime":"2026-08-24 12:05","pubTimestamp":1787544330,"startTime":"0","endTime":"0","summary":"麦科医药-B（02335）8月24日公告称，根据恒生指数有限公司在2026年8月21日公布的截至2026年6月30日止期间恒生指数系列季度检讨结果，公司H股将被纳入恒生综合指数，生效日期为2026年9月7日。\n公司表示，纳入恒生综合指数后，其H股预计将符合资格被纳入沪港通及深港通，为香港与内地资本市场投资者提供交易渠道。\n董事会认为，此次纳指显示资本市场对公司价值及成长潜力的认可，并有助于拓宽股东基础及提升H股交易流动性。\n公司提醒股东及潜在投资者在买卖公司股份时保持审慎。公告由公司主席、首席执行官兼执行董事王冰于2026年8月24日签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140356227","title":"陕西麦科医药科技（02335.HK）将于2026年9月7日纳入恒生综合指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1140356227","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140356227?lang=zh_cn&edition=full","pubTime":"2026-08-24 12:05","pubTimestamp":1787544313,"startTime":"0","endTime":"0","summary":"陕西麦科医药科技股份有限公司传来重磅消息——该公司将被正式纳入恒生综合指数，这一变动自2026年9月7日起生效。此次将陕西麦科医药科技纳入其中，无疑是对该公司市值、流动性及行业代表性等多方面指标的肯定。总而言之，陕西麦科医药科技即将跻身恒生综合指数成分股行列，这不仅是对其过往经营成果的认可，更预示着其在资本市场新征程上的启航。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660454447","title":"港股异动 | 麦科医药-B(02335.HK)午后涨近6% 创新药XTL6001三登国际顶级学术舞台","url":"https://stock-news.laohu8.com/highlight/detail?id=2660454447","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660454447?lang=zh_cn&edition=full","pubTime":"2026-08-18 13:48","pubTimestamp":1787032087,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","02335","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107177771","title":"麦科医药-B（02335）主要产品XTL6001研究成果获EASD 2026及ASN Kidney Week 2026收录","url":"https://stock-news.laohu8.com/highlight/detail?id=1107177771","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107177771?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:45","pubTimestamp":1786963544,"startTime":"0","endTime":"0","summary":"麦科医药-B8月17日发布自愿性公告称，集团关键产品XTL6001的最新研究成果已获多项国际学术会议接纳并将作报告。EASD 2026将于2026年9月28日至10月2日在意大利米兰举行。此外，集团核心产品MT1013的相关研究成果曾获选于ASN Kidney Week 2025的Late-Breaking Research Posters环节展示。公司表示，XTL6001连续入选ADA、EASD及ASN等国际学术会议，标志着其在体重管理及肾脏病领域的研发进展迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481420","title":"麦科医药-B(02335.HK)：XTL6001的研究获接纳于EASD 2026及ASN KIDNEY WEEK 2026作报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660481420?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:40","pubTimestamp":1786963221,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147209","title":"麦科医药-B(02335.HK)8月28日举行董事会会议批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147209","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659147209?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:27","pubTimestamp":1786717626,"startTime":"0","endTime":"0","summary":"格隆汇8月14日丨麦科医药-B(02335.HK)宣布，公司将于2026年8月28日(星期五)举行董事会会议，藉以(其中包括)批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布，考虑派发中期股息的建议(如有)，以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260814/32335962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124062847","title":"麦科医药-B（02335）拟于8月28日召开董事会 审议2026年中期业绩及派息方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1124062847","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124062847?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:45","pubTimestamp":1786715131,"startTime":"0","endTime":"0","summary":"陕西麦科奥特医药科技股份有限公司（02335）8月14日公告称，公司董事会将于2026年8月28日（星期五）召开会议，主要议程包括：一、审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布；二、考虑派发中期股息的建议（如有）；三、处理其他事项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658896964","title":"港股异动 | 麦科医药-B(02335)涨超3% MT200605临床前及I期临床数据获接纳于WSC 2026大会作口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2658896964","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658896964?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:39","pubTimestamp":1786419558,"startTime":"0","endTime":"0","summary":"消息面上，8月10日，麦科医药-B发布公告，本集团自主研发的用于治疗急性缺血性脑卒中的注射用神经保护候选药物MT200605的临床前及I期临床数据，已获接纳于2026年第十八届世界卒中大会作口头报告。在MT200605的临床前及I期临床数据获接纳于WSC 2026上作口头报告的同时，MT200605用于急性缺血性脑卒中的II期临床试验已获得具有统计学意义及临床相关性的结果，并达到主要终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1878469433.USD","VXUS","BK4585","LU1815336091.USD","LU0757428866.USD","02335","KCAI","WSC","BK4129","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196396","title":"麦科医药-B：MT200605 临床前及I期临床数据将于世界卒中大会口头发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196396","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658196396?lang=zh_cn&edition=full","pubTime":"2026-08-11 08:57","pubTimestamp":1786409820,"startTime":"0","endTime":"0","summary":"8月10日，麦科医药-B（02335）发布公告，公司自主研发的用于治疗急性缺血性脑卒中的注射用神经保护候选药物MT200605的临床前及I期临床数据，已获接纳于2026年第十八届世界卒中大会作口头报告。该大会将于2026年10月21日至23日在韩国首尔举行，报告时间为10月21日上午8时至9时30分。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837365795.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837365795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.micot.cn","stockEarnings":[{"period":"1week","weight":-0.0831},{"period":"1month","weight":-0.1027},{"period":"3month","weight":0.4308},{"period":"ytd","weight":0.4308}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":-0.0255},{"period":"3month","weight":0.0423},{"period":"6month","weight":-0.0075},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"陕西麦科奥特医药科技股份有限公司(以下简称“麦科奥特”)于2007年1月在西安成立,现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业,致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业,聚焦于心脑血管、代谢性疾病、炎症疼痛相关疾病新药的研发。公司致力于创制新药、挽救生命,满足未被满足的临床需求,用科技创新为人类健康保驾护航。\n麦科奥特作为一家平台型生物技术公司,致力于加速全球新一代双特异性/多特异性多肽药物的创新及开发,我们的核心产品处于Ⅲ期临床试验。自2007年成立以来,我们专注于代谢性疾病(尤其是肾脏相关疾病)以及心脑血管疾病,作为提出双/多特异性肽技术概念的全球先驱,并凭借进入临床开发的广泛候选产品管线,我们已在该领域确立领先地位。","exchange":"SEHK","name":"麦科医药-B","nameEN":"MICOT PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"麦科医药-B,02335,麦科医药-B股票,麦科医药-B股票老虎,麦科医药-B股票老虎国际,麦科医药-B行情,麦科医药-B股票行情,麦科医药-B股价,麦科医药-B股市,麦科医药-B股票价格,麦科医药-B股票交易,麦科医药-B股票购买,麦科医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}